Eli Lilly and Co. (Lilly), represented by Rentsch Partner (Christian Hilti, Demian Stauber und Andrea Carreira) fully succeeds against Sandoz Pharmaceuticals AG (Sandoz)
By decision of 15 October 2019, the Federal Patent Court (FPC) rejected the invalidity action of Sandoz against Lilly’s EP 1 313 508 concerning the cancer drug Pemetrexed (O2018_003 – not yet final). The FPC followed Lilly’s arguments and thus confirmed the validity of the patent. It disagreed with the decision of the German Federal Patent Court.
Before, Teva Pharma AG (Teva) hat tried to obtain a declaratory judgment for non-infringement against Lilly concerning the same patent, but without success, too. In that proceeding, Lilly was also successfully represented by Rentsch Partner and Teva’s action was rejected (O2015_004 from the 9 March 2017 / BGer 4A 208/2017 from the 20 October 2017 / BGE 143 III 666).
Rentsch Partner AG, Bellerivestrasse 203, 8008 Zürich
Postal address: P.O. Box, 8034 Zürich, Switzerland
Tel. +41 44 225 70 70, Fax +41 44 225 70 80
Copyright © 1997-2021 Rentsch Partner AG
The content on our web sites is protected by intellectual property rights (in particular copyright). Third-party content is marked as such. The content of our web sites must not be copied, disseminated, amended, made accessible to third parties or used in any other way without explicit written consent of Rentsch Partner Ltd., except where such use is explicitly permitted by the applicable law. Downloads, print-outs and copies of the content on our web site are allowed for private, non-commercial use only. The logo of Rentsch Partner Ltd. is a registered trademark. The content of our web sites have been compiled with accuracy. Nevertheless, Rentsch Partner Ltd. can not assume any guarantee regarding the correctness, completeness or quality of the provided information.